Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Financial performance
Oncology
Innovation: Pipeline overview
Financial review
Conclusion
Appendix
Innovation: Clinical trials
2021 key pipeline milestones¹
H1 2021
EntrestoⓇ
Regulatory
HFPEF (US)
decisions
and opinions
KesimptaⓇ
Relapsing MS (EU/JP)
Major
Leqvio®
Hyperlipidemia (US)²
expected
JakaviⓇ
submissions
TabrectaⓇ
BeovuⓇ
Asciminib (ABL001)
Acute and chronic GVHD (EU/JP)
NSCLC (EU)
DME (US/EU)
H2 2021
CosentyxⓇ
Pediatric psoriasis (US/CN/JP)
Achieved
Mixed results
Readout not supportive
✓ H2
CML 3L (US/EU)
CosentyxⓇ
JIA (US/EU)
Asciminib (ABL001)
BeovuⓇ
CML 3L (JP)
Alpelisib (BYL719)
KymriahⓇ
177Lu-PSMA-617
Tislelizumab (VDT482)
Tislelizumab (VDT482)
DME (JP)
PROS (US)
r/r Follicular lymphoma (US/EU/JP) ✓
mCRPC (US/EU)
2L esophageal cancer (US)
NSCLC (EU/US)
Major
Iptacopan (LNP023)
Ph2 - IgAN
expected
trial
readouts*
Iptacopan (LNP023) Ph2 - C3G
H2
EntrestoⓇ
Ph3 - Post-AMI
5
Canakinumab (ACZ885)
ECF843
Ligelizumab (QGE031)
Ph3 - NSCLC 1L
H1 20223
9
Canakinumab
(ACZ885)
->
Ph3 NSCLC 2L
7
KisqaliⓇ
-
Ph2 - Dry eye
Ph3 - CSU
Ph3 aBC (MONALEESA-2 OS)
4
6
177 Lu-PSMA-617
Ph3-mCRPC
CosentyxⓇ
Ph3 - JIA
Remibrutinib (LOU064)
CosentyxⓇ
Ph2 - CSU
Ph3 - HS
✓
✓
Sabatolimab (MBG453) Ph2 - MDS8
KymriahⓇ
Ph3 aNHL 2L
2. Resubmitted to FDA. 3. H1 2022 EU submission, H2 2022 2L US
*Achieved = on-time readout of data, irrespective of trial outcome. 1. 2021 Key milestone table may evolve based on read-out outcomes as well as BD&L activities.
submission. 4. Program discontinued in broad population of moderate to severe DED. 5. Numerical trends consistently favored EntrestoⓇ vs. active comparator but did not meet primary composite endpoint. The safety profile of EntrestoⓇ
was confirmed. No submission planned. 6. Ligelizumab demonstrated superiority compared with placebo PEARL 1 and PEARL 2 trials, but not versus omalizumab, further evaluating PEARL data. 7. Negative readout. 8. Planned DMC
readout for CR completed, study continues blinded to PFS readout, with submission in 2022/2023 using PFS and/or OS outcomes of Ph2 and/or Ph3 trial. 9. Ph3 study did not meet primary endpoints. PFS and OS trends support further
evaluation with additional analyses ongoing.
57 Investor Relations | Q4 2021 Results
U NOVARTIS | Reimagining MedicineView entire presentation